Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

REVBW

Revelation Biosciences (REVBW)

Revelation Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REVBW
DateTimeSourceHeadlineSymbolCompany
17/05/202406:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBWRevelation Biosciences Inc
11/05/202406:57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBWRevelation Biosciences Inc
11/05/202406:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REVBWRevelation Biosciences Inc
16/08/202207:30GlobeNewswire Inc.Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate ProgressNASDAQ:REVBWRevelation Biosciences Inc
30/07/202201:45GlobeNewswire Inc.Revelation Biosciences Inc. Announces Closing of $5 Million Public OfferingNASDAQ:REVBWRevelation Biosciences Inc
26/07/202222:15GlobeNewswire Inc.Revelation Biosciences Inc. Announces Pricing of $5 Million Public OfferingNASDAQ:REVBWRevelation Biosciences Inc
23/07/202208:30GlobeNewswire Inc.Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic RhinitisNASDAQ:REVBWRevelation Biosciences Inc
14/07/202223:00GlobeNewswire Inc.Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic RhinitisNASDAQ:REVBWRevelation Biosciences Inc
13/06/202223:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic RhinitisĀ NASDAQ:REVBWRevelation Biosciences Inc
23/05/202223:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic RhinitisNASDAQ:REVBWRevelation Biosciences Inc
17/05/202206:01GlobeNewswire Inc.Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate ProgressNASDAQ:REVBWRevelation Biosciences Inc
06/04/202223:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate UpdateNASDAQ:REVBWRevelation Biosciences Inc
31/03/202200:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza InfectionNASDAQ:REVBWRevelation Biosciences Inc
25/03/202200:00GlobeNewswire Inc.Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza InfectionNASDAQ:REVBWRevelation Biosciences Inc
23/03/202200:00GlobeNewswire Inc.Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLCNASDAQ:REVBWRevelation Biosciences Inc
16/03/202200:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza InfectionNASDAQ:REVBWRevelation Biosciences Inc
09/03/202201:00GlobeNewswire Inc.Revelation Biosciences Inc. to Present at the 34th Annual Roth ConferenceNASDAQ:REVBWRevelation Biosciences Inc
08/02/202201:00GlobeNewswire Inc.Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor ConferenceNASDAQ:REVBWRevelation Biosciences Inc
25/01/202200:00GlobeNewswire Inc.Revelation Biosciences Raises $7.76 Million in Equity FinancingNASDAQ:REVBWRevelation Biosciences Inc
21/01/202201:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza InfectionNASDAQ:REVBWRevelation Biosciences Inc
19/01/202201:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic RhinitisNASDAQ:REVBWRevelation Biosciences Inc
14/01/202205:54GlobeNewswire Inc.REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public CompanyNASDAQ:REVBWRevelation Biosciences Inc
12/01/202201:00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public CompanyNASDAQ:REVBWRevelation Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:REVBW